Sign in to use this feature.

Years

Between: -

Subjects

remove_circle_outline
remove_circle_outline

Journals

Article Types

Countries / Regions

Search Results (1)

Search Parameters:
Keywords = diclofenac disodium

Order results
Result details
Results per page
Select all
Export citation of selected articles as:
19 pages, 1951 KiB  
Review
Topical Immunotherapy for Actinic Keratosis and Field Cancerization
by Laura Bernal Masferrer, Tamara Gracia Cazaña, Isabel Bernad Alonso, Marcial Álvarez-Salafranca, Manuel Almenara Blasco, María Gallego Rentero, Ángeles Juarranz de la Fuente and Yolanda Gilaberte
Cancers 2024, 16(6), 1133; https://doi.org/10.3390/cancers16061133 - 12 Mar 2024
Cited by 4 | Viewed by 3717
Abstract
This comprehensive review delves into various immunotherapeutic approaches for the management of actinic keratoses (AKs), precancerous skin lesions associated with UV exposure. Although there are treatments whose main mechanism of action is immune modulation, such as imiquimod or diclofenac, other treatments, apart from [...] Read more.
This comprehensive review delves into various immunotherapeutic approaches for the management of actinic keratoses (AKs), precancerous skin lesions associated with UV exposure. Although there are treatments whose main mechanism of action is immune modulation, such as imiquimod or diclofenac, other treatments, apart from their main effect on dysplastic cells, exert some immunological action, which in the end contributes to their efficacy. While treatments like 5-fluorouracil, imiquimod, photodynamic therapy, and nicotinamide are promising in the management of AKs, especially in immunocompetent individuals, their efficacy is somewhat reduced in solid organ transplant recipients due to immunosuppression. The analysis extends to optimal combination, focusing on cryoimmunotherapy as the most relevant. New immunotherapies include resimiquimod, ingenol disoxate, N-phosphonacetyl-L-aspartate (PALA), or anti-PD1 that have shown promising results, although more studies are needed in order to standardize their use. Full article
(This article belongs to the Special Issue Topical and Intralesional Immunotherapy for Skin Cancer)
Show Figures

Figure 1

Back to TopTop